---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020508"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:08:41.139441+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology Q1 net loss $34.1M; ziftomenib enrollment outperforming projections

## Summary
- Net loss $34.1M vs $32.5M YoY; R&D expense $25.2M; cash $405.9M provides runway into Q4 2025.
- Phase 2 registration trial of ziftomenib in NPM1-mutant AML enrollment exceeding initial projections; 85-patient target.
- Updated Phase 1 ziftomenib data to be presented at EHA June 2023; 6/20 NPM1-mutant patients achieved CR at RP2D.
- FDA cleared IND for KO-2806, a next-generation FTI; FIT-001 Phase 1 trial expected to dose first patients H2 2023.
- First combination study KOMET-007 (ziftomenib + standards of care) to dose first patients in Q2 2023.

## SEC filing metadata
- accession: 0000950170-23-020508
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000095017023020508/0000950170-23-020508-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000095017023020508/kura-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020508
- JSON: https://secwatch.observer/filing/0000950170-23-020508.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020508.txt

## Key facts
- Earnings Releases
  Kura Oncology, Inc. reported first quarter ended March 31, 2023 results: net income $34.1 million.
  - Period: first quarter ended March 31, 2023
  - Net income: $34.1 million
  - Result: reported results
  source text: Net loss for the first quarter of 2023 was $34.1 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000095017023020508/0000950170-23-020508-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.